Eli Lilly and Company (NYSE:LLY) Trading Up 1.1% After Analyst Upgrade

Eli Lilly and Company (NYSE:LLY)’s stock price was up 1.1% during trading on Friday after Truist Financial raised their price target on the stock from $1,000.00 to $1,033.00. Truist Financial currently has a buy rating on the stock. Eli Lilly and Company traded as high as $920.70 and last traded at $920.34. Approximately 454,142 shares were traded during trading, a decline of 85% from the average daily volume of 3,000,219 shares. The stock had previously closed at $910.69.

Several other brokerages have also recently commented on LLY. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $1,025.00 price target on shares of Eli Lilly and Company in a research report on Thursday, October 3rd. Barclays boosted their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Berenberg Bank boosted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a report on Friday, August 9th. Finally, Guggenheim upped their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $979.29.

Hedge Funds Weigh In On Eli Lilly and Company

Several large investors have recently modified their holdings of the business. Able Wealth Management LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $75,000. Raleigh Capital Management Inc. increased its position in shares of Eli Lilly and Company by 241.9% during the fourth quarter. Raleigh Capital Management Inc. now owns 506 shares of the company’s stock worth $295,000 after buying an additional 358 shares during the period. Sierra Summit Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $3,726,000. Integrated Advisors Network LLC increased its position in shares of Eli Lilly and Company by 2.3% during the fourth quarter. Integrated Advisors Network LLC now owns 11,780 shares of the company’s stock worth $6,867,000 after buying an additional 270 shares during the period. Finally, Centaurus Financial Inc. increased its position in shares of Eli Lilly and Company by 1.8% during the fourth quarter. Centaurus Financial Inc. now owns 2,003 shares of the company’s stock worth $1,167,000 after buying an additional 35 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The company’s 50-day moving average price is $910.84 and its two-hundred day moving average price is $852.86. The company has a market capitalization of $885.83 billion, a price-to-earnings ratio of 137.27, a PEG ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. The company had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. On average, equities research analysts anticipate that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.